611 related articles for article (PubMed ID: 25269710)
1. Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type.
Johnson C; Connors GR; Oaks J; Han S; Truong A; Richardson B; Lechtzin N; Mammen AL; Casciola-Rosen L; Christopher-Stine L; Danoff SK
Respir Med; 2014 Oct; 108(10):1542-8. PubMed ID: 25269710
[TBL] [Abstract][Full Text] [Related]
2. Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response.
Bauhammer J; Blank N; Max R; Lorenz HM; Wagner U; Krause D; Fiehn C
J Rheumatol; 2016 Aug; 43(8):1566-74. PubMed ID: 27252419
[TBL] [Abstract][Full Text] [Related]
3. Clinical Profiles and Prognosis of Patients with Distinct Antisynthetase Autoantibodies.
Shi J; Li S; Yang H; Zhang Y; Peng Q; Lu X; Wang G
J Rheumatol; 2017 Jul; 44(7):1051-1057. PubMed ID: 28461650
[TBL] [Abstract][Full Text] [Related]
4. Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group.
Trallero-Araguás E; Grau-Junyent JM; Labirua-Iturburu A; García-Hernández FJ; Monteagudo-Jiménez M; Fraile-Rodriguez G; Les-Bujanda I; Rodriguez-Carballeira M; Sáez-Comet L; Selva-O'Callaghan A;
Semin Arthritis Rheum; 2016 Oct; 46(2):225-231. PubMed ID: 27139168
[TBL] [Abstract][Full Text] [Related]
5. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
[TBL] [Abstract][Full Text] [Related]
6. Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China.
Zhan X; Yan W; Wang Y; Li Q; Shi X; Gao Y; Ye Q
BMC Pulm Med; 2021 Feb; 21(1):57. PubMed ID: 33579248
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease.
Cavagna L; Caporali R; Abdì-Alì L; Dore R; Meloni F; Montecucco C
J Rheumatol; 2013 Apr; 40(4):484-92. PubMed ID: 23418387
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
9. Interstitial lung disease and myositis-specific and associated autoantibodies: Clinical manifestations, survival and the performance of the new ATS/ERS criteria for interstitial pneumonia with autoimmune features (IPAF).
Mejía M; Herrera-Bringas D; Pérez-Román DI; Rivero H; Mateos-Toledo H; Castorena-García P; Figueroa JE; Rojas-Serrano J
Respir Med; 2017 Feb; 123():79-86. PubMed ID: 28137500
[TBL] [Abstract][Full Text] [Related]
10. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome.
Lega JC; Fabien N; Reynaud Q; Durieu I; Durupt S; Dutertre M; Cordier JF; Cottin V
Autoimmun Rev; 2014 Sep; 13(9):883-91. PubMed ID: 24704867
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD).
Rojas-Serrano J; Herrera-Bringas D; Mejía M; Rivero H; Mateos-Toledo H; Figueroa JE
Clin Rheumatol; 2015 Sep; 34(9):1563-9. PubMed ID: 26219488
[TBL] [Abstract][Full Text] [Related]
12. Antisynthetase syndrome with anti-Jo1 antibodies in 48 patients: pulmonary involvement predicts disease-modifying antirheumatic drug use.
Stanciu R; Guiguet M; Musset L; Touitou D; Beigelman C; Rigolet A; Costedoat-Chalumeau N; Allenbach Y; Hervier B; Dubourg O; Maisonobe T; Charuel JL; Behin A; Herson S; Amoura Z; Grenier P; Benveniste O
J Rheumatol; 2012 Sep; 39(9):1835-9. PubMed ID: 22859355
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary Involvement in the Antisynthetase Syndrome: A Comparative Cross-sectional Study.
Andersson H; Aaløkken TM; Günther A; Mynarek GK; Garen T; Lund MB; Molberg Ø
J Rheumatol; 2016 Jun; 43(6):1107-13. PubMed ID: 27036381
[TBL] [Abstract][Full Text] [Related]
14. [The shades of anti-Jo1 positive antisynthetase syndrome in a Hungarian cohort].
Szabó K; Nagy-Vincze M; Bodoki L; Hodosi K; Dankó K; Griger Z
Orv Hetil; 2016 Apr; 157(15):575-83. PubMed ID: 27039996
[TBL] [Abstract][Full Text] [Related]
15. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody.
Marie I; Hatron PY; Dominique S; Cherin P; Mouthon L; Menard JF; Levesque H; Jouen F
Semin Arthritis Rheum; 2012 Jun; 41(6):890-9. PubMed ID: 22078416
[TBL] [Abstract][Full Text] [Related]
16. Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome.
Zamora AC; Hoskote SS; Abascal-Bolado B; White D; Cox CW; Ryu JH; Moua T
Respir Med; 2016 Sep; 118():39-45. PubMed ID: 27578469
[TBL] [Abstract][Full Text] [Related]
17. Clinical characterisation of a multicentre nationwide cohort of patients with antisynthetase syndrome.
Martins P; Dourado E; Melo AT; Samões B; Sousa M; Freitas R; Lourenço MH; Fernandes B; Costa E; Parente H; Martins F; Fonseca JE; Cordeiro I; Romão VC; Khmelinskii N; Campanilho-Marques R
ARP Rheumatol; 2022 Nov; 1(ARP Rheumatology, nº3 2022):190-196. PubMed ID: 35891592
[TBL] [Abstract][Full Text] [Related]
18. [Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases].
Xie MM; Zou RY; Li Y; Liu Y; Chen LL; Liu XQ; Zhao Q; Ding JJ; Chen ZY; Cai HR
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Oct; 42(10):765-770. PubMed ID: 31594111
[No Abstract] [Full Text] [Related]
19. Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls.
Labirua A; Lundberg IE
Curr Opin Rheumatol; 2010 Nov; 22(6):633-8. PubMed ID: 20827201
[TBL] [Abstract][Full Text] [Related]
20. Interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in Anti-Jo1 antibody-positive polymyositis patients: a single centre study and review of the literature.
Ingegnoli F; Lubatti C; Ingegnoli A; Boracchi P; Zeni S; Meroni PL
Autoimmun Rev; 2012 Mar; 11(5):335-40. PubMed ID: 21985773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
